| Unique ID issued by UMIN | UMIN000054497 |
|---|---|
| Receipt number | R000062255 |
| Scientific Title | Multicenter study to evaluate the efficacy and safety of combination therapy with LHRH antagonist, androgen-receptor signaling inhibitor, and denosumab followed by local radiation therapy in patients with multiple metastatic prostate cancer |
| Date of disclosure of the study information | 2024/05/28 |
| Last modified on | 2025/11/28 13:43:15 |
Multi-institutional study to evaluate the efficacy and safety of hormone therapy with radiation therapy for prostate cancer with multiple bone metastases
Efficacy of multidisciplinary treatment including radiotherapy for prostate cancer with multiple bone metastases
Multicenter study to evaluate the efficacy and safety of combination therapy with LHRH antagonist, androgen-receptor signaling inhibitor, and denosumab followed by local radiation therapy in patients with multiple metastatic prostate cancer
Efficacy of multidisciplinary treatment including radiotherapy for prostate cancer with multiple bone metastases
| Japan |
Patients with prostate cancer who had multiple bone metastases
| Urology |
Malignancy
NO
The aim of this study is to evaluate the utility and safety of the combination enzalutamide and ADT as a first-line treatment followed by RT for prostate in patients with mCSPC who had high-volume bone metastasis.
Efficacy
Exploratory
Pragmatic
Not applicable
Efficacy of this combination treatments on oncological outcomes
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
| Medicine | Maneuver |
Degarelix, Denosumab, Enzarutamide, Radiation
| 20 | years-old | <= |
| 90 | years-old | >= |
Male
histologically confirmed PCa with high burden synchronous metastatic disease (4 and more bone metastases), Eastern Cooperative Oncology Group performance status of 0-1, adequate bone marrow function (absolute neutrophil count 1500/m3 and more and platelet count 100000/m3 and more), adequate renal function (creatinine 2.0 mg/dL and less and/or creatinine clearance 40 mL/min and more), and adequate hepatic function (total bilirubin 1.5 mg/dL and less).
Patients who had previously undergone RT for the prostate or pelvis, or had received chemotherapy or hormonal therapy for PCa, were excluded. The patients who received finasteride or dutasteride before the surgery were also excluded from the present study.
30
| 1st name | Takuya |
| Middle name | |
| Last name | Koie |
Gifu University Graduate School of Medicine
Urology
5011194
1-1 Yanagido, Gifu, Japan
0582306000
koie.takuya.h2@f.gifu-u.ac.jp
| 1st name | Makoto |
| Middle name | |
| Last name | Kawase |
Gifu University Graduate School of Medicine
Urology
5011194
1-1 Yanagido, Gifu, Japan
0582306000
kawase.makoto.g5@f.gifu-u.ac.jp
Department of Urology, Gifu University Graduate School of Medicine
Takuya Koie
Astelas pharmacy
Profit organization
Gifu University Graduate School of Medicine
1-1 Yanagido, Gifu, Japan
0582306000
koie.takuya.h2@f.gifu-u.ac.jp
NO
| 2024 | Year | 05 | Month | 28 | Day |
Partially published
https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70355
35
No longer recruiting
| 2021 | Year | 06 | Month | 14 | Day |
| 2021 | Year | 08 | Month | 04 | Day |
| 2021 | Year | 12 | Month | 01 | Day |
| 2027 | Year | 12 | Month | 31 | Day |
| 2024 | Year | 05 | Month | 28 | Day |
| 2025 | Year | 11 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062255
| Research Plan | |
|---|---|
| Registered date | File name |
| 2024/11/27 | documents.pdf |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| 2024/11/28 | polymets data 元.xlsx |
| Research case data | |
|---|---|
| Registered date | File name |
| 2024/11/28 | polymets data.xlsx |
Value
https://center6.umin.ac.jp/ice/62255